We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Amarillo Biosciences Releases Corporate Progress Report

Amarillo Biosciences Releases Corporate Progress Report

Amarillo Biosciences Releases Corporate Progress Report

Amarillo Biosciences Releases Corporate Progress Report

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Amarillo Biosciences Releases Corporate Progress Report"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MacReport Media Publishing Amarillo Biosciences, Inc. (ABI) has announced that the treatment phase in its Phase 2 dose-ranging clinical trial of 169 hepatitis C patients has been completed.

Subjects were given low-dose oral interferon or placebo for 24 weeks to judge the effect on the relapse rate in hepatitis C patients who achieved virologic remission after treatment with Ribavirin and high-dose injectable interferon.

The treatments will be unblinded after subjects complete a 6-month untreated observation period, with final results expected in early 2012. Currently, there are no FDA-approved products for preventing relapse in hepatitis C patients after initial treatment.

Relapse can be as high as 60% with some genotypes of hepatitis C virus, so a product that reduces the relapse rate will address a major unmet medical need.

ABI is actively seeking funding for oral interferon research in the area of viral respiratory diseases as a follow-up to positive findings from the company's flu treatment and prevention study conducted in Australia.

One planned target of study is the annual Hajj pilgrimage, during which millions of Muslims travel from 120 countries to Mecca and Medina in Saudi Arabia.

The congregation of these pilgrims from many different countries results in widespread symptomatic respiratory tract infections, which puts a tremendous strain on Saudi Arabia's medical facilities.

"Our product offers a possible solution to this critical problem because animal studies have shown that low-dose oral interferon reduces the severity and duration of viral respiratory tract disease during comingling," stated Dr. Joseph M. Cummins, President and CEO of ABI.

In other developments, the company has engaged Interactive Business Alliance, LLC of San Diego to help with public relations and communications services.

Moreover, KracklePop Design of Roswell, New Mexico has been engaged to help create the branding for ABI's new dietary supplement that promotes health and enhances immunity, which is to be launched later this year.